Results 131 to 140 of about 33,038 (222)

Improved Chemosensitivity in Metastatic Castration-Resistant Prostate Cancer: The Synergistic Effects of S-Adenosylmethionine and Cabazitaxel. [PDF]

Cancer Med
Arpino R, Cadoni F, Pagano C, Coppola L, Del Vecchio V, Nigam A, Mosca L, Porcelli M.   +7 more
europepmc   +1 more source

TLN1 interacts with NGFR and suppresses the development of castration-resistant prostate cancer by upregulating NGFR. [PDF]

Front Immunol
Li S, Chen A, Guo C, Gu C, Tang Z, Shen S, Yang D, Mi Y.   +7 more
europepmc   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer. [PDF]

Mol Oncol
Gordon N, Gallagher PT, Richter OI, Poudel Neupane N, Mandigo AC, McCann JJ, Dylgjeri E, Vasilevskaya I, McNair C, Paller CJ, Kelly WK, Knudsen KE, Schiewer MJ, Shafi AA.   +13 more
europepmc   +1 more source

Immunotherapy in metastatic castration-resistant prostate cancer: transformative for the few, not for all. [PDF]

Transl Androl Urol
de Souza VPB, Barata PC.
europepmc   +1 more source

Bone-Modifying Agents in Metastatic Castration-Resistant Prostate Cancer.

JAMA Netw Open
Ozay ZI, Jo Y, Gebrael G, Ostrowski M, Mathew Thomas V, Li H, Graf RP, Roy S, Maughan BL, Guha A, Riaz IB, Antonarakis ES, McKay RR, Agarwal N, Swami U.   +14 more
europepmc   +1 more source

Novel Immunotherapeutic Strategies for Castration-Resistant Prostate Cancer: Mechanisms and Clinical Advances. [PDF]

Curr Issues Mol Biol
Xia X, Xia Z, Yu L.
europepmc   +1 more source

Cardiotoxicity risk in metastatic castration-resistant prostate cancer: enzalutamide versus abiraterone. [PDF]

Cardiooncology
Bryce AH, Nimke D, Young C, Shao Q, Rozario N, Kamdar P, Ivanova J, Varghese I, Touya M.   +8 more
europepmc   +1 more source

Prognostic value of PSMA PET-derived tumor volume in metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide. [PDF]

Cancer Imaging
Atasever T, Babacan GB, Ekinci ÖB, Buyukkuscu A, Uslu BS, Kabaca FZY, Atcı MM, Karyagar S, Ertürk K, Çelik E.   +9 more
europepmc   +1 more source

Sequential nanocatalytic therapy and lysosomal dysfunction for overcoming castration-resistant prostate cancer. [PDF]

Bioact Mater
Di J, Lee W, Xu Y, Kong H, Zhou F, Xu J, Chen X, Lao YH, Shao D, Xie X, Yao H, Tao Y, Li M.   +12 more
europepmc   +1 more source

Nicotinamide N-methyltransferase as a therapeutic target in taxane-resistant castration-resistant prostate cancer. [PDF]

Cell Death Discov
Cevatemre B, Karyemez E, Bulut I, Syed H, Gönen M, Baykal AT, Bagci-Onder T, Acilan C.   +7 more
europepmc   +1 more source